Follows Korean adults taking atogepant to prevent migraine
Studies safety and effect of atogepant in Korean adults with migraine in routine care.
Plain-language title generated from the registry record
Registry title: Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine
Key facts
- Where
- Ansan-si, Busan, Changwon-si, Daegu, Daejeon, Gangwon-do, Goyang, Goyang-si, Gwangju, Hwaseong, Hwaseong-si, Iksan, Incheon, Jeonju, Seongnam-si, Seoul, Suwon, Uijeongbu-si, and Yongin-si, South KoreaSee the 36 sites
Where in South Korea
- Korea University Ansan Hospital /ID# 284725Ansan-si, South KoreaTaking people
- Dong-A University Medical Center /ID# 275321Busan, South KoreaTaking people
- On Hospital /ID# 285157Busan, South KoreaTaking people
- Ryu Sang Hyo Neurosurgery Clinic /ID# 284804Busan, South KoreaTaking people
- Changwon Fatima Hospital /ID# 284572Changwon-si, South KoreaTaking people
- Daegu Catholic University Medical Center /ID# 284728Daegu, South KoreaTaking people
- Keimyung University Dongsan Hospital /ID# 284727Daegu, South KoreaTaking people
- Chungnam National University Hospital /ID# 284724Daejeon, South KoreaTaking people
- Chuncheon Sacred Heart Hospital /ID# 275315Gangwon-do, South KoreaTaking people
- Inje University - Ilsan Paik Hospital /ID# 280738Goyang, South KoreaTaking people
- National Health Insurance Corporation Ilsan Hospital /ID# 285128Goyang-si, South KoreaTaking people
- Chonnam National University Hospital /ID# 275318Gwangju, South KoreaTaking people
- Hallym University Dongtan Sacred Heart Hospital /ID# 273581Hwaseong, South KoreaTaking people
- Hallym University Dongtan Sacred Heart Hospital /ID# 280737Hwaseong, South KoreaTaking people
- Life Neurology Clinic /ID# 284729Hwaseong-si, South KoreaTaking people
- Teunteun Hospital /ID# 284730Hwaseong-si, South KoreaTaking people
- Wonkwang University Hospital /ID# 284567Iksan, South KoreaTaking people
- Gachon University Gil Medical Center /ID# 284571Incheon, South KoreaTaking people
- Inha University Hospital /ID# 275320Incheon, South KoreaTaking people
- The Catholic University of Korea, Incheon St. Mary's Hospital /ID# 284568Incheon, South KoreaTaking people
- Jeonbuk National University Hospital /ID# 273583Jeonju, South KoreaTaking people
- Seoul National University Bundang Hospital /ID# 284508Seongnam-si, South KoreaTaking people
- Ewha Womans University Medical Centre /ID# 275317Seoul, South KoreaTaking people
- Hallym University Kangdong Sacred Heart Hospital /ID# 284573Seoul, South KoreaTaking people
- Kangbuk Samsung Hospital /ID# 271893Seoul, South KoreaTaking people
- Korea University Anam Hospital /ID# 284726Seoul, South KoreaTaking people
- Korea University Guro Hospital /ID# 284569Seoul, South KoreaTaking people
- Nowon Eulji Medical Center, Eulji University /ID# 275316Seoul, South KoreaTaking people
- Samsung Medical Center /ID# 272640Seoul, South KoreaTaking people
- Seoul National University Hospital /ID# 271892Seoul, South KoreaTaking people
- Seoul National University Hospital /ID# 272638Seoul, South KoreaTaking people
- Yonsei University Health System Severance Hospital /ID# 272639Seoul, South KoreaTaking people
- Ajou University Hospital - Suwon-si /ID# 284574Suwon, South KoreaTaking people
- Hwahong Hospital /ID# 284803Suwon, South KoreaTaking people
- Uijeongbu Eulji Medical Center - Eulji University /ID# 284855Uijeongbu-si, South KoreaTaking people
- Yongin Severance Hospital /ID# 284570Yongin-si, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AbbVie
- Trial code
- NCT06603558
- Record updated
- 22 July 2026
- Original description
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound. The study will assess the safety and effectiveness of atogepant for the preventive treatment of migraine in Korean adult patients with chronic migraine or episodic migraine under routine clinical practice.Read full original descriptionShow less
Post-marketing Surveillance Study to Evaluate the Safety and Effectiveness of Atogepant for the Prevention of Migraine in Korean Adult Patients
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound. The study will assess the safety and effectiveness of atogepant for the preventive treatment of migraine in Korean adult patients with chronic migraine or episodic migraine under routine clinical practice.
Atogepant is an approved drug for preventive treatment of migraine in adults. Approximately 3000 adult participants who are prescribed atogepant by their doctors will be enrolled in this study in Korea.
Participants will receive atogepant oral tablets as prescribed by their physician. Participants will be followed for up to week 12.
There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
Inclusion: Participants with migraine suitable for the treatment with atogepant according to the latest approved local label; Participants prescribed atogepant in accordance with the approved local label.
Exclusion: Participants with any contraindication to atogepant as listed on the latest approved local label; Participants currently participating in another clinical research except observational study.